Veterinary Medicines: Northern Ireland

Debate between Gavin Robinson and Emma Hardy

Wednesday 3rd December 2025 Westminster Hall

[The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Emma Hardy)]

It is such a pleasure to serve under your chairwomanship, Dr Allin-Khan, and to respond to the debate. I thank the hon. Member for South Antrim (Robin Swann) for securing this debate on a highly important matter and for his continued commitment to the veterinary medicine supply in Northern Ireland. He might have noticed I am not the farming Minister, but I am pleased to be here to respond on her behalf.

I recognise how important this issue is to the people of Northern Ireland and all the communities the hon. Gentleman represents. He has raised many important issues with me today; I will endeavour to address as many as possible. Baroness Hayman was in Northern Ireland just last week meeting the hon. Gentleman and many of our organisations. She met vets, the Minister of Agriculture, Environment and Rural Affairs, the permanent secretary, and the Northern Ireland Business Brexit Working Group to demonstrate how important the issue is to the UK Government. Those channels of dialogue remain open.

I thank industry stakeholders for their ongoing support and work to make the changes necessary to continue supply to Northern Ireland. We have done extensive work with industry, which has given us the confidence in the arrangements we have put in place to manage a smooth transition into 2026. Before responding to specific questions raised in the debate, I want first to outline the Government’s view on veterinary medicine in Northern Ireland.

Safeguarding the supply of veterinary medicine in Northern Ireland after the grace period ends remains a core Government priority. We are committed to ensuring that the health and welfare of all animals is maintained in all circumstances. We are aware of concerns raised about pack size, discontinued products and the potential for increased costs, and we take those concerns extremely seriously. We have engaged extensively with stakeholders on those issues. Based on the evidence available to us through this engagement, our view remains that disruption at the end of the grace period will be limited and the arrangements we have in place will manage supply into 2026.

[Gavin Robinson]

I am grateful to the Minister for taking the intervention. Does she accept that the fundamental flaw in the Government’s approach is to accept the premise that the European Union controls what access there should be from one part of our United Kingdom to another and that we are accepting that there should be a chink in the UK internal market? Does she understand that when the grace period comes to an end, the European Union cannot and will not be able to demonstrate any detriment to their single market because of the ongoing availability until the end of this year. There has not been any detriment to their single market because of the availability of veterinary medicines from GB to Northern Ireland; and nor will there be, so all this is wholly disproportionate and unnecessary.

[Emma Hardy]

I thank the right hon. Member. He will recognise that it is important for the UK to be legally compliant with all of our international agreements. We take seriously the Windsor framework and the rules that it gave our country. I would not want to be part of a Government who disregard international agreements, but I completely understand his concerns around veterinary medicines.

We expect 10% to 15% of currently licensed veterinary medicines in Northern Ireland to be discontinued, but most are either dormant and not sold in Northern Ireland or have multiple alternatives available. We have analysed each discontinuation against multiple criteria to determine the position. However, we appreciate we can never have perfect data and that situations change. That is why we have also announced the veterinary medicines internal market scheme and the veterinary medicine health situation scheme: to help to address any gaps, should they arise.

The veterinary medicines internal market scheme removes administrative burdens from vets moving medicine that are not vaccines from Great Britain to Northern Ireland when, in their clinical judgment, that is needed. It is based on the existing cascade procedure, with which vets are very familiar. These simplifications allow the scheme to be as responsible as possible when managing supply issues.

The veterinary medicine health situation scheme allows the Government to temporarily authorise an alternative medicine when a discontinuation is expected to lead to a health situation. It is designed to provide a dedicated supply mechanism to address supply issues, should they arise.